An Open-Label, Single-Centre, Phase I Study to Assess the Excretion, Metabolism and Plasma Pharmacokinetics Following a Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2010
At a glance
- Drugs AZD 9668 (Primary)
- Indications Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 02 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2010 New trial record